Alexander Aravanis net worth and biography

Alexander Aravanis Biography and Net Worth

Alex Aravanis Ph.D. serves as Chief Technology Officer of the Company. Dr. Aravanis brings almost 20 years of experience in leading research and development efforts, spanning basic research and technology development through late stage clinical development, and is returning to Illumina from GRAIL, Inc. which he co-founded, and serves as the Chief Scientific Officer and Head of Research and Development. At GRAIL, he led the teams developing its multi-cancer early detection test by combining high-intensity sequencing approaches of unprecedented breadth and depth, and the latest tools of data science and data engineering, including powerful approaches from machine learning, such as neural networks. He and the GRAIL team created one of the largest clinical study programs ever in genomic medicine to support development of its products. Prior to GRAIL, Dr. Aravanis served in R&D for Illumina and developed multiple technologies, including clinical assays and bioinformatic pipelines for the analysis of RNA and DNA from fixed tissues, whole exome analysis, massively parallel single cell transcriptomics and liquid biopsy using cell-free nucleic acids. Dr. Aravanis holds a B.S. in Electrical Engineering, Computer Science, and Physics Minor from the University of California, Berkeley, as well as an M.S. and Ph.D. in Electrical Engineering, and an M.D. from Stanford University.

What is Alexander Aravanis' net worth?: The estimated net worth of Alexander Aravanis is at least $343,130.46 as of February 22nd, 2023. Dr. Aravanis owns 2,922 shares of Illumina stock worth more than $343,130 as of April 19th. This net worth evaluation does not reflect any other investments that Dr. Aravanis may own. Learn More about Alexander Aravanis' net worth.
How do I contact Alexander Aravanis?: The corporate mailing address for Dr. Aravanis and other Illumina executives is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. Illumina can also be reached via phone at (858) 202-4500 and via email at [email protected]. Learn More on Alexander Aravanis' contact information.
Has Alexander Aravanis been buying or selling shares of Illumina?: Alexander Aravanis has not been actively trading shares of Illumina during the last ninety days. Most recently, Alexander Aravanis sold 5,398 shares of the business's stock in a transaction on Wednesday, February 22nd. The shares were sold at an average price of $201.74, for a transaction totalling $1,088,992.52. Following the completion of the sale, the senior vice president now directly owns 2,922 shares of the company's stock, valued at $589,484.28. Learn More on Alexander Aravanis' trading history.
Who are Illumina's active insiders?: Illumina's insider roster includes Alexander Aravanis (SVP), Frances Arnold (Director), Charles Dadswell (SVP), Francis deSouza (CEO), Phillip Febbo (SVP), Jay Flatley (Director), Aimee Hoyt (SVP), Karen Mcginnis (CAO), Robert Ragusa (SVP), Mostafa Ronaghi (SVP), Sam Samad (CFO), Susan Tousi (SVP), and Mark Van Oene (SVP). Learn More on Illumina's active insiders.
Are insiders buying or selling shares of Illumina?: In the last year, Illumina insiders bought shares 1 times. They purchased a total of 7,330 shares worth more than $991,675.70. In the last year, insiders at the life sciences company sold shares 4 times. They sold a total of 1,815 shares worth more than $314,104.60. The most recent insider tranaction occured on February, 22nd when CEO Jacob Thaysen bought 7,330 shares worth more than $991,675.70. Insiders at Illumina own 0.2% of the company. Learn More about insider trades at Illumina.
Information on this page was last updated on 2/22/2024.

Alexander Aravanis Insider Trading History at Illumina

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/22/2023	Sell	5,398	$201.74	$1,088,992.52	2,922
7/7/2022	Sell	539	$200.00	$107,800.00	3,346
11/12/2021	Sell	361	$386.35	$139,472.35
11/2/2021	Sell	2,926	$412.78	$1,207,794.28
10/26/2021	Sell	2,926	$423.00	$1,237,698.00
10/19/2021	Sell	2,926	$411.82	$1,204,985.32
10/12/2021	Sell	2,926	$409.21	$1,197,348.46
7/7/2021	Sell	539	$477.59	$257,421.01

Alexander Aravanis Buying and Selling Activity at Illumina

Illumina Company Overview

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Today's Range

Now: $117.43

$116.61

$119.22

50 Day Range

MA: $133.78

$116.69

$146.07

2 Week Range

Now: $117.43

$89.00

$229.58

Volume

1,398,759 shs

Average Volume

1,754,530 shs

Market Capitalization

$18.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Forget NVIDIA, buy this $2 AI stock now…

From Behind the Markets | Ad

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

Click here to learn more >>>